Introduction
Ewing's sarcoma belongs to the Ewing's sarcoma family of tumors (ESFT). It is the second most frequent bone and soft tissue sarcoma, affecting mostly adolescents and young adults. Ewing's sarcoma is characterized by unique chromosomal translocations involving fusion of the 5'segment of the Ewing's sarcoma breakpoint region 1 (EWS) gene to the 3'segment of an E26 transformation-specific (ETS) family gene, with the most common fusion taking place with friend leukemia integration 1 transcription factor (FLI1) (1) . Although the 5-year survival rate of Ewing's sarcoma has been improved through multimodal therapy, patients with metastasis at diagnosis still have poor clinical outcomes (2) (3) (4) . It has been hypothesized that the EWS-FLI1 fusion protein is involved in a key oncogenic event in ESFT by inducing and repressing specific target genes (5-7), thereby promoting tumor growth. Although previous studies have identified the factors that modulate or are modulated by EWS-FLI1 (8) (9) (10) , the mechanisms underlying the development of Ewing's sarcoma are not yet fully understood.
Several studies have suggested that the EWS-FLI1 fusion gene is implicated in Ewing's sarcoma by modulating microRNA (miRNA/miR) expression (11) (12) (13) . miRNAs are a class of small noncoding RNAs that regulate gene expression by targeting mRNA (14, 15) . Although the biological functions of miRNAs remain largely unknown, there is some evidence that miRNAs can act as oncogenes or tumor suppressor genes to regulate cell proliferation, differentiation, apoptosis and metastasis by altering expression of their target genes (16, 17) . Since miRNAs can be regulated by EWS-FLI1, they may represent potential downstream targets in Ewing's sarcoma (11) (12) (13) 18, 19) .
The miR-34 family is a collection of evolutionarily conserved miRNAs, which has been associated with tumor suppression and is downregulated in human tumors (20) (21) (22) . miR-34a, a member of miR-34 family, has been reported to predict the survival of patients with Ewing's sarcoma, and directly affects the chemosensitivity of tumor cells and malignancy (23) . However, miR-34b has not been specifically detected in Ewing's sarcoma. The aim of the present study was to investigate the effects of miR-34b, as well as those of its direct target gene, Notch1, in promoting Ewing's sarcoma growth and metastasis (24, 25) .
MicroRNA-34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1
Materials and methods Transfection. RD-ES and A-673 Cells (1x10 5 /L) were transfected with 20 nM small interfering RNA (siRNA) (Shanghai GeneChem Co., Ltd., Shanghai, China) targeting EWS-FLI-1 using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The RNA sequences used are as follows: EWS-FLI-1-specific siRNA, sense 5'-GUA CCC UUC UGA CAU CUC CUT T-3', antisense 5'-AGG AGU GUC AGA AGG GUA CTT-3'; and non-silencing control siRNA, sense 5'-UUC UCC GAA CGU GUC ACG UTT-3' and antisense 5'-ACG UGA CAC GUU CGG AGA ATT-3'. Infected cells were incubated for 24 h at 37˚C and used for further experiments.
The precursor (miRBase accession no. MI0000742) or complementary miR-34b sequence (miRBase accession no. MIMAT0000685) was inserted into a lentiviral vector (Shanghai Genechem Co., Ltd., Shanghai, China; cat. nos. PMUL217000742 and PMDL159000685, respectively) to up-or downregulate miR-34b expression as previously described (26) . [Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease]. The cells were infected with the lentiviral vectors (1x10 8 TU/ml) according to manufacturer's protocol.
Reverse transcription-polymerase chain reaction (RT-PCR)
and RT-quantitative PCR. Total RNA was extracted from cell lines and tumor and normal tissue biopsy samples using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol, and the RNA was subsequently reverse-transcribed into complementary DNA using SuperScript™ First-Strand Synthesis System (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 11904-018; Table I ). For reverse transcription reactions, 10 ng total RNA was used in each reaction (5 µl) and mixed with the RT primer (3 µl). The RT reaction was carried out at 16˚C for 30 min; 42˚C for 30 min; 85˚C for 5 min; and then maintained at 4˚C. The specific primers used for EWS-FLI1, EWS-ERG and miR amplification are summarized in Table II . The amplified PCR products were separated by 1.5% agarose gel electrophoresis and visualized in gel with ethidium bromide under ultraviolet light. RT-qPCR was performed using an ABI Prism7300 Sequence Detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the GoTaq qPCR Master Mix A6001 kit (Promega Corporation, Madison, WI, USA). The following thermocycling conditions were used: Denaturation at 95˚C for 15 min, followed by 40 cycles of amplification at 95˚C for 15 sec and 58˚C for 30 sec for extension, followed by maintenance at 4˚C. GAPDH and U6 was used as an endogenous control and reference gene for relative quantifications of the 2 -ΔΔCq analysis method (27) . Experiments were performed in triplicate.
Western blot analysis. Western blot analysis was performed as previously described (13) . Briefly, Ewing's sarcoma cells and 3T3 cells were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay lysis buffer (20 mmol/l of Tris-HCl, 150 mmol/l of NaCl, 1% NP-40, 5 mmol/l of EDTA, and 1 mmol/l of Na 3 VO 4 , pH 7.5) containing protease inhibitor cocktail (Sigma-Aldrich; Merck KGaA) and then incubated for 25 min at 4˚C and centrifuged for 20 min at 13,000 x g at 4˚C. Thereafter, the supernatant was recovered and quantified using the Pierce bicinchoninic acid protein quantification assay (Pierce; Thermo Fisher Scientific, Inc.). An aliquot (50-100 mg of protein per lane) of the total protein was loaded onto 10% SDS-PAGE and then blotted to polyvinylidene fluoride membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Individual immunoblots were performed with primary antibodies against Notch1 (1:1,000; cat. no. ab8925; Abcam, Cambridge, MA, USA), Hes family BHLH transcription factor 1 (1:1,000; Hes1; cat. no. ab71559; Abcam), Hes-related family BHLH transcription factor with YRPW motif 1 (1:1,000; Hey1; cat. no. ab22614; Abcam) and β-actin (1:2,000; cat no. sc-130065; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Briefly, membranes were blocked in Tris-buffered saline with 20% Tween (TBST) buffer containing 5% nonfat dry milk for 2 h at room temperature and incubated overnight with primary antibody. Subsequently, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.) for 1 h. Enhanced chemiluminescent reagent (GE Healthcare, Chicago, IL, USA) was used for protein visualization. Experiments were performed in triplicate. Cell proliferation and adhesion assays. Cell proliferation was determined by the MTT assay. Following infection by EWS-FLI-1 siRNA and miR-34b precursor or inhibitor, Cells were trypsinized and 5x10 3 cells/well were seeded into 96-well plates in triplicate. Cellular proliferation was determined once a day over the course of 5 days. Briefly, 20 µl 5 mg/ml MTT was added to each well and cells were incubated at 37˚C in a humidified atmosphere containing 5% CO 2 . Cells were lysed after 4-6 h using cell lysis reagent (20% sodium dodecyl sulfate, 50% dimethyl sulfoxide, pH 4.7), and absorbance was measured at 570 nm with an EL-311SX microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
The adhesion assay was performed using MTT-stained cells. At 24 h following infection by siRNA targeting EWS/FLI1 and miR-34b precursor or inhibitor at 37˚C, the Ewing sarcoma cells (1x10 5 ) were resuspended in 200 ml medium without serum and seeded into a Matrigel-precoated (100 mg/ml) 96-well plate. Cells were washed after 30 and 60 min to remove non-adherent cells. After the final wash, absorbance was measured at 490 nm to quantify adherence. Experiments were repeated three times.
Cell migration and invasion assays. Migration assays for A673 or RD-ES cells were performed by seeding 3x10
5 cells in 200 µl DMEM or RPMI serum-free medium in the upper chambers of 24-well Transwell inserts with polyethylene terephthalate membranes (8.0-µm pore size; Costar, Corning Inc., Corning, NY, USA). The lower chambers were filled with 0.8 ml DMEM or RPMI supplemented with 15% FBS. After 24 h incubation at 37˚C, the non-migrating cells were removed; and the membranes were fixed and stained using the Differential Quik Stain kit (Sysmex Corporation, Kobe, Japan). Cells that migrated through the membranes were quantified using NIKON LABOPHOT optical light microscopic visualization (magnification x200) and by randomly selecting 10 regions for cell counting. Experiments were performed in triplicate.
The procedure for the invasion assay was similar to the migration assay. Briefly, the membranes in the Transwell inserts were coated evenly with 25 µl Matrigel (100 mg/ml) per well (BD Biosciences, Franklin Lakes, NJ, USA; cat. no. 356234) before cells were seeded into the upper chamber. After incubation for 36 and 48 h for A673 and RD-ES cells, respectively, invaded cells on the lower surface of the membrane were analyzed as previously described in the migration assay.
Luciferase reporter assay. The 3'-untranslated region (UTR) of Notch1 was amplified from human genomic DNA and cloned into the pmiR-RB-REPORT™ reporter gene plasmid vector (Guangzhou RiboBio Co., Ltd., Guangzhou, China) with restriction enzymes XhoI and NotI. Similarly, a fragment representing mutant Notch1 3'-UTR, harbouring the change of the seven miRNA34b-binding sites (ACU GCC U→UGA CGG A), was cloned into the pmiR-RB-REPORT vector as a control. For reporter assays, 1x10 5 /l cells were plated in a 24-well culture plate at a density of 8,000 cells/well and co-transfected with the reporter plasmid and 100 nM miR-34b inhibitor or miR inhibitor negative control (NC) (NC sequence: 5'-UUG UAC UAC ACA AAA GUA CUG-3') which were synthesized by Shanghai GenePharma Co., Ltd., with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol Luciferase activity was measured 48 h post-transfection using the Dual-Luciferase ® Reporter Assay system (Promega Corporation, Madison, WI, USA), according to the manufacturer's protocol. Firefly luciferase activity was normalized against Renilla luciferase activity for each transfected well to normalize transfection efficiency.
Statistical analysis. The results of RT-qPCR, proliferation, adhesion, migration and invasion assays are presented as the means ± standard error. Each assay was performed in triplicate Data were analyzed by one-way analysis of variance. All statistical analyses were performed using the SPSS 13.0 statistical software package (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. 
Results

Expression levels of EWS-FLI1 and miR-34b in biopsy samples.
A large proportion (85-90%) of Ewing's sarcoma cases are characterized by the EWS-FLI1 fusion gene (28) . Therefore, the expression levels of the fusion gene were detected in Ewing's sarcoma and normal tissue (NT) biopsy samples using RT-PCR. The results demonstrated that NT did not express the EWS-FLI1 fusion gene (Fig. 1A ) and 3/14 tumor samples did express EWS-ERG fusion gene (Fig. 1B) . The results of 10 samples and 1 NT are presented in the Fig. 1A because the lanes of gel electrophoresis were limited in our laboratory. The expression levels of miR-34b in tumor samples and NT were measured using stem-loop RT-qPCR. The results demonstrated that tumor samples expressed increased levels of miR-34b compared with NT. Notably, miR-34b was expressed at higher levels in EWS-FLI1-positive samples compared within EWS-ERG-positive samples (Fig. 1C) . These results indicated that the EWS-FLI1 gene may have greater controlover miR-34 be xpression than the EWS-ERG gene.
EWS-FLI1 fusion gene may affect miR-34b expression in
Ewing's sarcoma cell lines. RD-ES and A673 cells are known to possess the EWS-FLI1 fusion gene (29) . Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles. NIH3T3 cells were detected as negative control. Therefore, EWS-FLI1 expression levels in these cell lines were detected using RT-PCR (Fig. 2A) . The expression of the fusion gene was successfully downregulated by siRNA in RD-ES cells and A673 cells (Fig. 2B) . In addition, the relative miR-34b expression levels were detected in cell lines with or without the interrupted fusion gene. As presented in the figure, miR-34b expression in RD-ES and A673 cells was downregulated following siRNA transfection (Fig. 2C and D) . These results indicated that the EWS-FLI1 fusion gene may be associated with miR-34b expression in Ewing's sarcoma cell lines, which is consistent with the observations made in the tumor biopsy samples.
Up-and downregulation of miR-34b expression. miR-34b expression can be controlled by the EWS-FLI1 fusion gene; in addition, in the present study its expression was altered using lentiviral vectors. The lentiviral vector with complementary sequences of miR-34b was infected into normal cells to downregulate miR-34b expression, whereas the lentiviral vector with precursor sequences of miR-34b was infected into siRNA-transfected cells to upregulate miR-34b expression. As shown in Fig. 2E and F, miR-34b expression was successfully up-and downregulated by precursor and complementary miR-34b sequences, respectively.
miR-34b promotes proliferation of Ewing's sarcoma cells in vitro.
To investigate the effects of miR-34b on proliferation of Ewing's sarcoma cell lines, an MTT assay was performed. The results demonstrated that when miR-34b expression was upregulated, the siRNA-transfected RD-ES and A673 cells in which EWS-FLI1 was downregulated exhibited a significant increase in proliferative capacity compared with the cells in the control groups (Fig. 3A and B) . Conversely, the proliferative ability of normal RD-ES and A673 cells was significantly inhibited when miR-34b expression was downregulated ( Fig. 3C and D) . These results indicated that miR-34b may promote cell proliferation in Ewing's sarcoma.
miR-34b promotes RD-ES, but not A673, cell adhesion in vitro.
The adhesion of cancer cells to the extracellular matrix has a significant role in metastasis after disaggregation from the primary tumor. Therefore, an inhibition of adhesion may contribute to a reduction in metastatic potential. The present study demonstrated that upregulation of miR-34b expression significantly increased the adhesion of RD-ES cells, whereas up-or downregulation of miR-34b had little effect on A673 cell adhesion (Fig. 3E and F) .
miR-34b improves the migration and invasion of Ewing's sarcoma cells in vitro.
Migration and invasion of tumor cells are indispensable for metastasis in vivo; therefore, inhibiting the migratory and invasive capacity of Ewing's sarcoma cells may decrease metastatic potential. In the present study, the effects of miR-34b on the migratory and invasive properties of Ewing's sarcoma cell lines were investigated using Transwell assays. As shown in Fig. 4 , the ability of RD-ES cells to migrate and invade was significantly inhibited when miR-34b expression was downregulated. Similar results were also obtained usingA673 cells (data not shown).
Effects of miR-34b on Notch1, Hes1 and Hey1 in Ewing's sarcoma cells.
To determine the molecular mechanisms involved in miR-34b-induced cell proliferation and migration, the Notch signaling pathway was investigated as it is a target of miR-34b and exhibits the opposite role in suppressing tumor development. When miR-34b expression was inhibited, the RT-qPCR results demonstrated that Notch1 expression was increased compared with the other three Notch receptors (data not shown). Therefore, the expression levels of Notch1, and its target genes, Hes1 and Hey1, in RD-ES and A673 cells were further assessed by RT-qPCR analysis. Compared with in normal cells, the expression levels of Notch1, Hes1and Hey1 were increased when the EWS-FLI1 fusion gene was silenced by siRNA in RD-ES and A673 cells (Fig. 5A) . Conversely, the expression levels of Notch1, Hes1 and Hey1 were decreased after the cells in which EWS/FLI1 expression was downregulated with the siRNA were transfected with miR-34b precursor sequences (Fig. 5B) . Furthermore, there was an increase in the expression levels of Notch1, Hes1 and Hey1 after miR-34b downregulation (Fig. 5C) .
The protein expression levels of Notch1, Hes1 and Hey1 were examined by western blot analysis. In agreement with the RT-qPCR data, it was also demonstrated that miR-34b was able to downregulate Notch1, Hes1 and Hey1 protein expression (Fig. 6) . These results suggested that the EWS-FLI1 fusion gene mayinactivate the Notch1 signaling pathway in Ewing's sarcoma via miR-34b.
miR-34b directly modulates expression of the Notch1 gene in Ewing's sarcoma cells in vitro.
A dual-luciferase reporter assay was conducted to confirm the effects of miR-34b on Notch1. Fragments containing the miR-34b binding sequence or mutated sequence in the 3'-UTR of the Notch1 mRNA were cloned into the pmiR-RB-REPORT luciferase reporter vector to generate the pmiR-RB-REPORT-NOTCH1-3'UTR and pmiR-RB-REPORT-NOTCH1-3'UTR-MUT plasmids, respectively. These reporter constructs were co-transfected with miR-34b inhibitor or miR-NC into RD-ES and A673 cells, and luciferase activity was measured. It was revealed that miR-34b inhibition led to significantly increased luciferase activity of pmiR-RB-REPORT-NOTCH1-3'UTR (P<0.05; Fig. 7 ), but had no effect on pmiR-RB-REPORT-NOTCH1-3'U TR-mut. Taken together, these results suggested that miR-34b may directly target the 3'-UTR of Notch1.
Discussion
Accumulating evidence has suggested that miRNA shave a key role in tumorigenesis through the regulation of their target genes. Previous studies involving in vitro experiments and analysis of clinical samples have demonstrated a direct link between miRNA function and the EWS-FLI1 fusion gene (11) (12) (13) 23) . In particular one member of the miR-34 family, miR-34a, has been reported to predict the survival of patients with Ewing's sarcoma (23) . Therefore, the present study aimed to investigate miR-34b expression in Ewing's sarcoma, a disease predominantly characterized by the EWS-FLI1 fusion gene (1) . Firstly, gene expression of the EWS-FLI1 gene in the NT samples was detected by RT-PCR followed by gel electrophoresis and the results indicated that the EWS-FLI1 fusion gene was not expressed in all NT samples. Subsequently, RT-PCR was performed to detect the expression levels of miR-34b using stem-loop primers. Notably, the expression levels of miR-34b were higher in tumor samples compared within NT samples. In addition, the expression levels of miR-34b were higher in EWS-FLI1-positive samples compared with in EWS-FLI1-negative samples. It has been demonstrated at the molecular level that ~10% of Ewing's sarcoma cases harbor the EWS-ERG fusion transcript (28, 30) . FLI1 and ERG belong to the ETS transcription factor family, which all share a highly conserved DNA-binding domain, and can act as aberrant transcription factors when their genes fuse with the EWS gene (1, (31) (32) (33) (34) . The difference inmiR-34b expression inEWS-FLI1-and EWS-ERG-positive samples may be associated with the differential regulatory abilities of the FLI1 and ERG genes (35) . miR-34b expression was also detected in Ewing's sarcoma cell lines and miR-34b expression was inhibited when the cells were transfected with EWS-FLI1-specific siRNA. These results indicated that miR-34b may be upregulated in Ewing's sarcoma biopsy samples, particularly those harboring the EWS-FLI1 fusion gene, and Ewing's sarcoma cell lines. The results were consistent with other studies demonstrating the involvement of miRNAs in Ewing's sarcoma as well as other solid tumors (11, 36) . Studies have demonstrated that miRNAs can act as oncogenes or tumor suppressor genes, and that widespread alterations in miRNA expression patterns are highly associated with various human cancers (37, 38) . miR-34b is a member of the evolutionarily conserved miR-34family, and can exert tumor suppressive effects by downregulating its target genes, including Notch, B-cell lymphoma 2andhigh mobility group AT-hook 2 (22) . miR-34b also has an important role in p53-induced cell cycle arrest, cell senescence, apoptosis and other biological functions (39) . Numerous studies have demonstrated that miR-34b inhibits cell proliferation, migration and invasion (20, 21, 40) ; however, miR-34b also has an oncogenic role in esophageal squamous cell carcinoma (41) . To the best of our knowledge, the functions of miR-34b in Ewing's sarcoma have not yet been elucidated.
Uncontrolled cell proliferation leads to tumor growth, and aggressive tumor cell metastasis promotes spreading of tumor cells to distal sites. Therefore, the present study investigated the role of miR-34b in proliferation, adhesion, migration and invasion of tumor cells. Firstly, the precursor sequence of miR-34b was infected into siRNA-transfected Ewing's sarcoma cells. The proliferative, migratory and invasive abilities of the cells were significantly enhanced following upregulation of miR-34b expression. The adhesive ability was also enhanced in RD-ES cells, but not in A673 cells. According to the ATCC, these cell lines possess different culture characteristics that could account for the differences observed. RD-ES cells grow as a loosely attached monolayer in small clusters, whereas A673 cells are fully adherent (42) . Subsequently, the complementary sequence was used to downregulate miR-34b expression and, as expected, the adhesive abilities were inhibited. These results indicated that miR-34b may serve an oncogenic role in Ewing's sarcoma.
Notch is an evolutionarily conserved signaling pathway that affects cell fate, proliferation, migration and invasion (43) . Notch can be oncogenic or tumor suppressive in human cancer (44) (45) (46) (47) ; therefore, the role of Notch needs to be further clarified in the context of different types of cancer. Previous studies have demonstrated that suppression of EWS-FLI1 reactivates Notch signaling in ESFT cells, resulting in cell cycle arrest (48) , and using microarray analysis, Notch signaling has been revealed to be crucial for the metastatic phenotype (49) . SinceNotch1 is expressed in ESFT cell lines (48, 50) and is a target gene of miR-34b (25, 51, 52) , the present study investigated the expression levels of Notch1in A673 and RD-ES cell lines. The results indicated that suppression of EWS-FLI1 couldincreaseNotch1expression at both the mRNA and protein levels. Conversely, when miR-34b expression was upregulated, the mRNA and protein levels of Notch1 were decreased. It has previously been reported that Hey1 is the main downstream effector of Notch signaling and that Hes1 is uncoupled from the Notch pathway in ESFT cells (53) . In the present study, the observation was made that the mRNA and protein expression levels of Hes1 and Hey1 were downregulated by miR-34b, indicating that the EWS-FLI1 fusion gene may suppress the Notch1 signaling pathway, at least in part via miR-34b. miRNAs can function as either tumor suppressor genes or oncogenes depending on their target genes (54, 55) . Tumor suppressive miRNAs that target tumor-promoting genes are repressed in cancer, whereas oncogenic miRNAs that target tumor suppressor genes are upregulated in cancer. For tumors where Notch1 serves an oncogenic role (44, 56) , miR-34 has been demonstrated to be tumor suppressive (25, 51, 57) . Therefore, as Notch1 acts as a tumor suppressor in Ewing's sarcoma, miR-34b may be exerting its oncogenic effects through this gene. Using a dual-luciferase reporter assay, it was revealed that miR-34b may directly modulate the expression of Notch1 by binding to the 3'-UTR region (sequence 181-187) of Notch1.
Despite overexpression of miR-34b in Ewing's sarcoma samples and cell lines, the underlying mechanisms by which EWS-FLI1 affects miR-34b remain unclear. miR-34 has been reported to be directly induced by the c-MYC proto-oncogene, which is a known EWS-FLI1 target gene (58) , thus suggesting that EWS-FLI1 may indirectly modulate miR-34b via c-Myc induction. In conclusion, EWS-FLI1 may modulate miR-34b expression through direct or indirect mechanisms, and miR-34b appears to serve an oncogenic role in Ewing's sarcoma by downregulating Notch1.
